Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.39 |
| ▸ | TGM1 | P22735 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27478625 | 0.89 | POLB (0.44) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL17790245 | 0.83 | P2RX7 (0.48) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL13575643 | 0.82 | NR1H2 (0.47) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL10007648 | 0.82 | P2RX7 (0.51) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL601417 | 0.82 | P2RX7 (0.47) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL31568967 | 0.82 | P2RX7 (0.47) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL10183072 | 0.82 | NR1H2 (0.47) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL31569288 | 0.81 | NR1H2 (0.46) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL19005602 | 0.81 | NR1H2 (0.46) | NR1H2POLBMAPTCKS1BSKP1 | |
| SCHEMBL28887447 | 0.81 | NR1H2 (0.49) | NR1H2POLBMAPTCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | NR1H2 616/4885POLB 3631/4885MAPT 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.